Kazia Therapeutics (KZIA) Operating Leases (2016 - 2017)

Kazia Therapeutics' (KZIA) quarterly Operating Leases came in at $165913.9 in Q4 2017, up 40.18% YoY from $118355.5 in Q4 2016, and up 40.18% on a QoQ basis from $118355.5 in Q4 2016.

Kazia Therapeutics (KZIA) Operating Leases (2016 - 2017) Analysis & Trends

Kazia Therapeutics (KZIA) has 2 years of Operating Leases data on file, last reported at $165913.9 in Q4 2017.

  • Quarterly Operating Leases rose 40.18% year-over-year to $165913.9 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $165913.9 (up 40.18% YoY) and the FY2016 annual result came in at $118355.5, changed N/A from the prior year.
  • Operating Leases rose to $165913.9 in Q4 2017, from $118355.5 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $165913.9 in Q4 2017 to a low of $118355.5 in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Kazia Therapeutics 4.22 Bn 4.22 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2017 165,913.92
Dec 31, 2016 118,355.49